<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Pediatr Nephrol</journal-id>
      <journal-title>Pediatric Nephrology (Berlin, Germany)</journal-title>
      <issn pub-type="ppub">0931-041X</issn>
      <issn pub-type="epub">1432-198X</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">16247644</article-id>
      <article-id pub-id-type="pmc">1766475</article-id>
      <article-id pub-id-type="publisher-id">2082</article-id>
      <article-id pub-id-type="doi">10.1007/s00467-005-2082-7</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Editorial Commentary</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Prevention and treatment of renal osteodystrophy in children on chronic renal failure: European guidelines</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name name-style="western">
            <surname>Klaus</surname>
            <given-names>G.</given-names>
          </name>
          <address>
            <phone>+49-6421-2862670</phone>
            <fax>+49-6421-2865427</fax>
            <email>klaus@med.uni-marburg.de</email>
          </address>
          <xref ref-type="aff" rid="Aff13">13</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Watson</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff9">9</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Edefonti</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Fischbach</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>R&#xF6;nnholm</surname>
            <given-names>K.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schaefer</surname>
            <given-names>F.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Simkova</surname>
            <given-names>E.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Stefanidis</surname>
            <given-names>C. J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Strazdins</surname>
            <given-names>V.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff7">7</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Vande Walle</surname>
            <given-names>J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff8">8</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Schr&#xF6;der</surname>
            <given-names>C.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff10">10</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zurowska</surname>
            <given-names>A.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff11">11</xref>
        </contrib>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ekim</surname>
            <given-names>M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff12">12</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Fondazione IRCCS Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, Milan, Italy </aff>
        <aff id="Aff2"><label>2</label>Hospital de Hautepierre, Strasbourg, France </aff>
        <aff id="Aff3"><label>3</label>University of Helsinki, Helsinki, Finland </aff>
        <aff id="Aff4"><label>4</label>University of Heidelberg, Heidelberg, Germany </aff>
        <aff id="Aff5"><label>5</label>University Hospital Motol, Prague, Czech Republic </aff>
        <aff id="Aff6"><label>6</label>A&amp;P Kyriakou Children&#x2019;s Hospital, Athens, Greece </aff>
        <aff id="Aff7"><label>7</label>University Hospital for Children, Riga, Latvia </aff>
        <aff id="Aff8"><label>8</label>University of Ghent, Ghent, Belgium </aff>
        <aff id="Aff9"><label>9</label>Nottingham City Hospital, Nottingham, UK </aff>
        <aff id="Aff10"><label>10</label>Wilhelmina Kinderziekenhuis, University of Utrecht, Utrecht, The Netherlands </aff>
        <aff id="Aff11"><label>11</label>University of Gdansk, Gdansk, Poland </aff>
        <aff id="Aff12"><label>12</label>University of Ankara, Ankara, Turkey </aff>
        <aff id="Aff13"><label>13</label>Department of Pediatrics, University of Marburg, Deutschhausstrasse 12, 35033 Marburg, Germany </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>25</day>
        <month>10</month>
        <year>2005</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>2</month>
        <year>2006</year>
      </pub-date>
      <volume>21</volume>
      <issue>2</issue>
      <fpage>151</fpage>
      <lpage>159</lpage>
      <history>
        <date date-type="received">
          <day>23</day>
          <month>11</month>
          <year>2004</year>
        </date>
        <date date-type="rev-recd">
          <day>28</day>
          <month>6</month>
          <year>2005</year>
        </date>
        <date date-type="accepted">
          <day>29</day>
          <month>6</month>
          <year>2005</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; IPNA 2005</copyright-statement>
      </permissions>
      <abstract>
        <p>Childhood renal osteodystrophy (ROD) is the consequence of disturbances of the calcium-regulating hormones vitamin D and parathyroid hormone (PTH) as well as of the somatotroph hormone axis associated with local modulation of bone and growth cartilage function. The resulting growth retardation and the potentially rapid onset of ROD in children are different from ROD in adults. The biochemical changes of ROD as well as its prevention and treatment affect calcium and phosphorus homeostasis and are directly associated with the development of cardiovascular disease in pediatric renal patients. The aims of the clinical and biochemical surveillance of pediatric patients with CRF or on dialysis are prevention of hyperphosphatemia, avoidance of hypercalcemia and keeping the calcium phosphorus product below 5&#xA0;mmol<sup>2</sup>/l<sup>2</sup>. The PTH levels should be within the normal range in chronic renal failure (CRF) and up to 2&#x2013;3 times the upper limit of normal levels in dialysed children. Prevention of ROD is expected to result in improved growth and less vascular calcification.</p>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Chronic renal failure</kwd>
        <kwd>Secondary hyperparathyroidism</kwd>
        <kwd>Calcium-phosphate product</kwd>
        <kwd>Vitamin D</kwd>
        <kwd>Parathyroidectomy</kwd>
      </kwd-group>
      <custom-meta-wrap>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; IPNA 2006</meta-value>
        </custom-meta>
      </custom-meta-wrap>
    </article-meta>
  </front>
  <body>
    <sec id="Sec2">
      <title>Introduction</title>
      <p>Chronic renal failure is associated with specific abnormalities of skeletal homeostasis, commonly called renal osteodystrophy (ROD), which if not treated appropriately during the critical phases of skeletal growth can result in bone deformities and a disturbed growth pattern. The main factors for the development of ROD are disturbances in the calcium phosphate homeostasis, in vitamin D and parathyroid hormone metabolism as well as alterations in the somatotroph axis, i.e., on the endocrine and paracrine levels. In recent years it has been recognized that the spectrum of renal bone disease covers &#x2018;high-&#x2019; as well as &#x2018;low-turnover&#x2019; conditions. As a consequence of chronic renal failure itself and of the treatment of renal bone disease, high plasma phosphate levels and an elevated calcium phosphorus product are common. These are important risk factors for the development of vascular calcification and cardiovascular morbidity and mortality in young adults who have been on renal replacement therapy since childhood [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Because aluminium-containing phosphate binders are no longer indicated in children, aluminium-related osteopathy is not considered in these recommendations.</p>
      <p>The European Pediatric Peritoneal Working Group (EPPWG) was established in 1999 by pediatric nephrologists with a major interest in peritoneal dialysis and has, among others, published guidelines on chronic and acute peritoneal dialysis [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>]. The group incorporates pediatric nephrologists from 12 European countries. One of the functions of the group is to establish expert guidance in important clinical areas associated with chronic renal failure and dialysis [now the European Pediatric Dialysis Working Group (EPDWG)] in conjunction with other members of the multidisciplinary team. These guidelines were initiated and discussed at meetings of the group and developed by e-mail discussion to develop consensus of opinion based upon cumulative clinical experience and reported studies.</p>
    </sec>
    <sec id="Sec3">
      <title>Recommendations</title>
      <sec id="Sec4">
        <title>Recommendation 1</title>
        <p><bold>Clinical, biochemical and radiological markers of renal bone disease should be monitored regularly.</bold> The clinical markers of renal bone disease to be prevented are signs of overt rickets, slipped femoral epiphysis and disturbances of growth. The biochemical markers are plasma phosphate, calcium, alkaline phosphatase, bicarbonate and intact parathyroid hormone (PTH). The minimal frequency of measurements (and target ranges) for biochemical markers in a stable phase vary according to renal function (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>). If the patient has active ROD, additional blood samples may be required.<table-wrap id="Tab1"><label> Table&#xA0;1</label><caption><p> Frequency of measurements for biochemical and radiological markers of renal osteodystrophy</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Marker<sup>1</sup></th><th colspan="3">Frequency of measurement (every x month)</th><th>Target</th></tr></thead><tbody><tr><td rowspan="2"/><td>GFR</td><td>GFR</td><td>GFR &lt;15, dialysis</td><td rowspan="2"/></tr><tr><td>59&#x2013;30</td><td>29&#x2013;15</td><td>(Evidence)</td></tr><tr><td>Calcium or</td><td rowspan="2">6</td><td rowspan="2">3</td><td rowspan="2">1</td><td>Normal range (corrected calcium)<sup>2</sup></td></tr><tr><td>Ionized calcium</td><td>Normal range<sup>2</sup></td></tr><tr><td>Phosphate</td><td>6</td><td>3</td><td>1</td><td>Normal range for age band</td></tr><tr><td rowspan="2">Calcium phosphorus product</td><td rowspan="2">6</td><td rowspan="2">3</td><td rowspan="2">1</td><td>&#x2264;5.0&#xA0;mmol<sup>2</sup>/l<sup>2</sup></td></tr><tr><td>Target range 3.3&#x2013;4.4&#xA0;mmol<sup>2</sup>/l<sup>2, 3</sup></td></tr><tr><td>Alkaline phosphatase</td><td>6</td><td>3</td><td>1</td><td>Normal range for age band</td></tr><tr><td rowspan="2">Serum bicarbonate/base excess</td><td rowspan="2">6</td><td rowspan="2">3</td><td rowspan="2">1</td><td>Normal range, at least: bicarbonate &gt;22&#xA0;mmol/l</td></tr><tr><td>Base excess &gt;&#x2212;5&#xA0;mmol/l</td></tr><tr><td rowspan="2">Intact PTH/whole PTH</td><td rowspan="2">6</td><td rowspan="2">3</td><td rowspan="2">1</td><td>Normal range in moderate CRF (GFR&gt;29&#xA0;ml/min/1.73m<sup>2</sup>)</td></tr><tr><td>Up to 2&#x2013;3 times upper limit of normal in advanced CRF or on dialysis</td></tr><tr><td>25-(OH) vitamin D<sub>3</sub></td><td>As indicated<sup>4</sup></td><td>As indicated<sup>4</sup></td><td>As indicated<sup>4</sup></td><td>&gt;20&#xA0;ng/l</td></tr><tr><td rowspan="2">Left hand and wrist X-ray</td><td rowspan="2"/><td rowspan="2"/><td rowspan="2">6&#x2013;12</td><td>No radiological signs of hyperparathyroidism</td></tr><tr><td>No Looser zones or osteopenia</td></tr></tbody></table><table-wrap-foot><p>Calcium: mmol/l in mg/dl: &#xD7;4, phosphate mmol/l in mg/dl: &#xD7;3.0969; calcium phosphorus product: mmol<sup>2</sup>/l<sup>2</sup> in mg<sup>2</sup>/l<sup>2</sup>: &#xD7;12.387. <sup>2</sup>Corrected calcium (mg/dl) = measured calcium concentration (mg/dl) + 0.8 &#xD7; [4-measured albumin concentration (g/dl)]; corrected calcium (mmol/l) = measured calcium concentration (mmol/l) +0.2 &#xD7; [4-measured albumin concentration (g/dl)]. <sup>3</sup>Depending on age. <sup>4</sup>Only in patients with suspected vitamin D deficiency</p></table-wrap-foot></table-wrap></p>
        <p>Plasma calcium must be adjusted for albumin levels (= corrected calcium) or by measuring ionized (free) calcium, in patients with hypoalbuminemia or acid-base disorders. Ionized calcium values are often available on blood gas analysis systems with calcium-sensitive electrodes, but correct values are only obtained in validated conditions. Alkaline phosphatase as a marker for osteoblast activity has particular importance in both low and high-turnover bone disease with elevated or low alkaline phosphatase serum levels, respectively.</p>
        <p>PTH should be monitored monthly in advanced CRF (GFR &lt;15&#xA0;ml/min/1.73m<sup>2</sup>) because of its rapid changes. Different assays are available for the measurement of PTH. In principle, intact PTH(1&#x2013;84) (iPTH) should be measured because it is believed to represent the active hormone. For this purpose, two-site assays were developed at the end of the 1980s [<xref ref-type="bibr" rid="CR7">7</xref>]. However, PTH fragments accumulating in end-stage renal disease may also show biological activity. Furthermore, recent research using plasma samples from healthy and renal patients analyzed by HPLC and the iPTH assay demonstrated cross-reactivity of the intact PTH-assay with a PTH-fragment (PTH7&#x2013;84). Therefore, new assays were developed that detect only PTH molecules with a complete N-terminal end, called &#x201C;whole-PTH&#x201D; assays [<xref ref-type="bibr" rid="CR8">8</xref>]. In adult and pediatric dialysis patients, these &#x201C;whole PTH&#x201D; assays yielded 30&#x2013;60% lower PTH levels than the intact PTH assay. Despite theoretical considerations, no significant improvement in the distinction between the different forms of renal bone disease using the &#x201C;whole PTH&#x201D; assays has yet been demonstrated in clinical practice [<xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR11">11</xref>, <xref ref-type="bibr" rid="CR12">12</xref>].</p>
        <p>Radiological signs of renal bone disease, which alone are not sensitive enough to indicate therapy-adaptations, include signs of hyperparathyroidism and growth zone lesions. Periosteal resorption zones and metaphyseal changes are the most obvious signs. In late adolescent and young adult patients, Looser zones as specific signs of osteomalacia may be found. The sites and expression of bone lesions are age-dependent according to the age-dependent growth and remodeling at different sites of the skeleton. In pre-school children, the metaphysis of the distal radius and ulna may present only minor abnormalities, whereas more severe lesions may be seen at the upper and lower femoral epiphysis. Adynamic bone disease shows no specific radiological changes. However, extraosseous calcifications, fractures or osteopenia may indicate adynamic bone disease.</p>
        <p>Histological evaluation of bone biopsy specimens remain the &#x201C;gold standard&#x201D; in assessment of renal osteodystrophy. However, due to its invasive nature, bone biopsies are not performed in clinical practice, but they remain an important tool for research [<xref ref-type="bibr" rid="CR12">12</xref>].</p>
      </sec>
      <sec id="Sec5">
        <title>Recommendation 2</title>
        <p><bold>Metabolic acidosis should be corrected (evidence).</bold> Chronic metabolic acidosis leads to increased bone resorption and inhibits endochondral bone formation in animal experiments [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Infants with isolated chronic metabolic acidosis show growth retardation [<xref ref-type="bibr" rid="CR14">14</xref>]. In adult hemodialysis patients, negative aspects of chronic metabolic acidosis on metabolism have been reported [<xref ref-type="bibr" rid="CR15">15</xref>]. Therefore, metabolic acidosis should be corrected by a stepwise approach: The first step is optimization of the dialysis regimen both for HD- and PD-patients [<xref ref-type="bibr" rid="CR4">4</xref>, <xref ref-type="bibr" rid="CR15">15</xref>]. Since the introduction of HCO<sub>3</sub>-based PD solutions [<xref ref-type="bibr" rid="CR16">16</xref>], metabolic acidosis is a less frequent problem. In combination with a daytime-dwell, patients may even be at risk for alkalosis [<xref ref-type="bibr" rid="CR17">17</xref>]. However, if these adaptations do not result in correction of the metabolic acidosis, sodium bicarbonate should be administered orally. Whenever possible, formulations that dissolve in the small intestine should be used. The use of sodium citrate increases the risk of aluminium absorption [<xref ref-type="bibr" rid="CR18">18</xref>, <xref ref-type="bibr" rid="CR19">19</xref>]. Acidosis should be corrected to the normal range of the local laboratory.</p>
      </sec>
      <sec id="Sec6">
        <title>Recommendation 3</title>
        <p><bold>The plasma-phosphate level should be kept within the normal age-specific range (evidence).</bold> In children with chronic renal failure, hyperphosphatemia is observed at GFR levels below 40&#xA0;ml/min/1.73m<sup>2</sup> [<xref ref-type="bibr" rid="CR20">20</xref>] and almost always in children on dialysis. Hyperhosphatemia has several deleterious effects on PTH secretion [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR22">22</xref>], parathyroid cell proliferation [<xref ref-type="bibr" rid="CR23">23</xref>] and soft tissue (vascular) calcification [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p>
        <p>Increased phosphate levels stimulate PTH secretion in vitro [<xref ref-type="bibr" rid="CR24">24</xref>] and in vivo [<xref ref-type="bibr" rid="CR21">21</xref>, <xref ref-type="bibr" rid="CR25">25</xref>] independent of calcium and 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> levels. This effect of phosphate on PTH secretion occurs via post-transcriptional processes by regulating pre-pro-PTH mRNA stability [<xref ref-type="bibr" rid="CR26">26</xref>]. Furthermore, a reduction of serum-phosphate results in a parallel reduction of PTH levels without change in serum calcium [<xref ref-type="bibr" rid="CR27">27</xref>]. Hyperphosphatemia accelerates parathyroid cell proliferation [<xref ref-type="bibr" rid="CR23">23</xref>], which can result in nodular hyperplasia and severe hyperparathyroid bone disease necessitating parathyroidectomy (see below).</p>
        <p>Increased plasma phosphate levels have a profound effect on soft tissue and vascular calcification, which are often observed in young patients on or even after dialysis [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR28">28</xref>], increasing the risk of cardiovascular morbidity and mortality. Block et al. [<xref ref-type="bibr" rid="CR29">29</xref>] found an increased risk of death for serum phosphate exceeding 2.09&#xA0;mmol/l in adult patients; other studies described a much lower phosphate level (~1.4&#x2013;1.6&#xA0;mmol/l) at which a higher incidence of calcifications was found [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>]. The histology of the calcification pattern is quite distinct from the process of atherosclerosis. In renal patients, extensive calcification of the tunica media occurs even after short periods of dialysis, as shown by investigations of the epigastric artery in adult patients [<xref ref-type="bibr" rid="CR32">32</xref>]. Experimental work gave evidence for an active role of phosphate in this process as phosphate induces osteoblastic marker followed by calcification in cultured smooth muscle cells [<xref ref-type="bibr" rid="CR33">33</xref>]. Dialysis patients are at risk of heart failure. Although this is a multifactorial process, it was demonstrated in animal experiments that high plasma phosphate levels per se accelerated cardiac fibrosis [<xref ref-type="bibr" rid="CR34">34</xref>].</p>
      </sec>
      <sec id="Sec7">
        <title>Recommendation 4</title>
        <p><bold>If plasma phosphate is elevated, phosphate intake should be limited to the recommended levels.</bold> Dietary intake of protein and as a consequence of phosphate in western countries usually exceeds the recommended intake at least in adolescent dialysis patients. Therefore, dietary counseling should be performed by a trained dietician [<xref ref-type="bibr" rid="CR35">35</xref>]. If the dietary records show a protein intake above the recommended level for pediatric dialysis patients, the patients and their parents should be trained to reduce their phosphate intake. This may start with the reduction of dairy products and/or substitution with special low-phosphorus products and a reduction of meat intake.</p>
      </sec>
      <sec id="Sec8">
        <title>Recommendation 5</title>
        <p><bold>In case of hyperphosphatemia, the dialysis efficacy should be optimized (evidence).</bold> Phosphate is slowly transported via the peritoneal membrane into the dialysate [<xref ref-type="bibr" rid="CR36">36</xref>]. The dialysate to plasma ratio (D/P) for phosphate is volume and time related; after 4&#xA0;h in standard peritoneal equilibration tests, this ratio reaches the value of 0.5&#x2013;0.6, which is a much lower ratio than for urea, which is usually nearly 1. Therefore, an increase in phosphate removal should consider not only an increase in dwell volume to 1,000&#x2013;1,400&#xA0;ml/m<sup>2</sup> BSA, but also dwell time optimization, avoiding a too short dwell time. A daytime dwell should be added. The details of a dialysis regimen optimization has been described elsewhere [<xref ref-type="bibr" rid="CR5">5</xref>]. However, due to the low clearance of phosphate achievable even with an optimized PD regimen, dietary phosphate restriction and the use of oral phosphate binders are almost always necessary.</p>
        <p>The dialytic phosphate removal kinetic during a hemodialysis session differs from urea kinetic: after an early initial drop the phosphatemia decrease only slowly [<xref ref-type="bibr" rid="CR37">37</xref>, <xref ref-type="bibr" rid="CR38">38</xref>]. Therefore, it is admitted that the hemodialysis phosphate purification capacity is directly impacted by the duration of the dialysis session, because the phosphate shift from the intracellular to the vascular compartment is time-dependent. Therefore, longer dialysis sessions [<xref ref-type="bibr" rid="CR39">39</xref>] or daily dialysis sessions [<xref ref-type="bibr" rid="CR40">40</xref>, <xref ref-type="bibr" rid="CR41">41</xref>, <xref ref-type="bibr" rid="CR42">42</xref>] offer a unique, powerful dialysis method for optimal phosphate purification. The hemodialysis modality, HD, HF or HDF, and the type of the synthetic membrane used have only a limited impact on dialytic phosphate removal [<xref ref-type="bibr" rid="CR38">38</xref>], whereas the dialysate composition in terms of glucose and bicarbonate concentration are presumed to be of importance [<xref ref-type="bibr" rid="CR42">42</xref>, <xref ref-type="bibr" rid="CR43">43</xref>, <xref ref-type="bibr" rid="CR44">44</xref>], modulating a shift of intracellular phosphate trapped in the cells, where it is not available for dialysis exchanges.</p>
      </sec>
      <sec id="Sec9">
        <title>Recommendation 6</title>
        <p><bold>For control of hyperphosphatemia, aluminium-free phosphate binders should be administered (evidence).</bold> Phosphate binders are necessary to reduce phosphate absorption from the gut. Ca-containing phosphate binders, i.e., calcium carbonate (CaCO<sub>3</sub>, elemental calcium content 40%) or calcium acetate (CaAc, elemental calcium content 25%) should be used as the first line. No data are published on the efficacy and safety of calcium acetate/magnesium carbonate compound phosphate binders in pediatric patients. The upper intake level of elemental calcium is suggested to be 2,500&#xA0;mg/day for healthy children above 4&#xA0;years of age [<xref ref-type="bibr" rid="CR19">19</xref>]. Whereas for adult dialysis patients the DOQI guidelines suggest to limit the elemental calcium intake to 2,000&#xA0;mg/day, no safe upper level can be given for the pediatric age band. However, a positive calcium balance in the range of +200&#x2013;+300&#xA0;mg in the growing skeleton should be maintained. In contrast, a too high calcium load should be avoided, because one of the identified risk factors for soft tissue calcification in pediatric CRI patients was cumulative calcium intake [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR24">24</xref>].</p>
        <p>Calcium-containing phosphate binders are started at approximately 500&#xA0;mg per 200&#xA0;mg phosphate content of the diet (0&#x2013;1&#xA0;years, 1&#x2013;2&#xD7;500&#xA0;mg; 1&#x2013;4&#xA0;years, 2&#x2013;3&#xD7;500&#xA0;mg/day; 5&#x2013;8&#xA0;years, 3&#x2013;4&#xD7;500&#xA0;mg/day; 9&#x2013;18&#xA0;years, 5&#xD7;500&#xA0;mg). An alternative approach is a start dose of approximately 50&#xA0;mg/kg/day, which is well below the doses given in clinical studies. Phosphate binders are then adjusted to normalize serum-phosphate and calcium. CaCO<sub>3</sub> can be crushed to fine powder, or a 10% solution can be used for administration in infants, often via a feeding tube. The phosphate binders should be taken with meals, because fecal excretion of phosphate was higher when calcium acetate was given with meals instead of in between meals [<xref ref-type="bibr" rid="CR45">45</xref>]. Biochemically, CaAc has a higher phosphate binding capacity, which is independent of the pH. The higher efficacy of CaAc, calculated on a weight basis compared to CaCO<sub>3</sub>, for phosphate control was also shown in clinical practice in adult and pediatric patients [<xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR47">47</xref>]. Unfortunately, compliance of the patients with the intake of phosphate binders is often poor and should be checked regularly. It may be helpful if the patient is involved in selecting the flavor and size of the phosphate binder and has regular contact with the dietician at clinic appointments. Snacks during the day are often a source of additional phosphate and require additional phosphate binders.</p>
        <p>Patients treated with Ca-containing phosphate binders and active vitamin D metabolites are particularly at risk for the development of hypercalcemia. Therefore, in case of hypercalcemia, active vitamin D metabolites should be stopped (see recommendation 12). If hypercalcemia, the most common side-effect of Ca-containing phosphate binder therapy, persists or the calcium phosphorus product exceeds 5.0&#xA0;mmol<sup>2</sup>/l<sup>2</sup> with the use of Ca-containing phosphate binders, the calcium content in the dialysis fluid should be reduced [<xref ref-type="bibr" rid="CR5">5</xref>]. Furthermore, the dose of the calcium-containing phosphate binders should be reduced whenever possible or they should be replaced by Ca- and aluminium-free phosphate binders, because epidemiological studies have shown a direct relationship between serum phosphate and calcium phosphorus product on mortality [<xref ref-type="bibr" rid="CR29">29</xref>, <xref ref-type="bibr" rid="CR48">48</xref>]. The only commercially available aluminium- and calcium-free phosphate binder is Sevelamer. This compound is usually taken orally as capsules, but anecdotally can be delivered via enteral tubes by dissolving the capsule in 5&#xA0;ml water (instruction Fa genzyme). Aluminium-containing phosphate binders or calcium citrate increase intestinal aluminium absorption and should not be used in pediatric dialysis patients. An alternative phosphate binder that is available is lanthanum carbonate, which has a high affinity for phosphate, and is minimally absorbed in the intestine. In a randomized study in adult patients, lanthanum carbonate controlled plasma phosphate levels well and induced less adynamic bone disease than CaCO<sub>3</sub> [<xref ref-type="bibr" rid="CR49">49</xref>]. However, no long-term data on the effect of lanthanum on bone, on which surface lanthanum can accumulate [<xref ref-type="bibr" rid="CR50">50</xref>], and its safety profile for use in children are available yet.</p>
      </sec>
      <sec id="Sec10">
        <title>Recommendation 7</title>
        <p><bold>Vitamin D deficiency should be avoided (evidence).</bold> In early renal failure, an increase of PTH correlates positively with 25(OH)-vitamin D<sub>3</sub> levels [<xref ref-type="bibr" rid="CR51">51</xref>]. Renal synthesis of 1,25(OH)<sub>2</sub> D<sub>3</sub> is impaired in chronic renal disease. However, extrarenal cells, i.e., macrophages and osteoblasts, are also capable of 1,25(OH)<sub>2</sub> D<sub>3</sub> production [<xref ref-type="bibr" rid="CR52">52</xref>]. In contrast to the kidney, the extra-renal synthesis is strictly substrate dependent. It has been shown that supplementation with vitamin D<sub>3</sub> in elderly CRF patients with 25(OH)-vitamin D<sub>3</sub> levels between 20 and 50&#xA0;pg/ml decreased PTH serum concentrations [<xref ref-type="bibr" rid="CR53">53</xref>]. Furthermore, 25-OH-vitamin D<sub>3</sub>, but not 1,25(OH)<sub>2</sub> D<sub>3</sub>, improved muscular function and phosphate content [<xref ref-type="bibr" rid="CR54">54</xref>]. Therefore, vitamin D deficiency should be prevented.</p>
      </sec>
      <sec id="Sec11">
        <title>Recommendation 8</title>
        <p><bold>Marked hyperparathyroidism should be prevented in children with CRF prior to dialysis (evidence).</bold> Due to the risk of persisting bone disease and the development of parathyroid adenoma, an increase in PTH above normal to slightly elevated levels should be prevented in children with CRF. Therefore, low doses of active vitamin D metabolites should be given in time. In adult patients this treatment regimen has resulted in controlled iPTH without negative aspects [<xref ref-type="bibr" rid="CR55">55</xref>]. In children with moderate renal failure (GFR &gt;30&#xA0;ml/min/1.73&#xA0;m<sup>2</sup>), normal levels of PTH in association with strictly controlled phosphate levels are associated with a normal ratio of intact PTH to &#x201C;whole&#x201D; PTH and normal levels of alkaline phosphatase, indicating a physiological PTH secretion and unremarkable bone turnover [<xref ref-type="bibr" rid="CR10">10</xref>]. In such patients, slight catch-up growth with PTH levels at the upper limit of normal was reported [<xref ref-type="bibr" rid="CR56">56</xref>]. In a sub-group analysis, improved growth was restricted to patients with enteral feeding tubes.</p>
      </sec>
      <sec id="Sec12">
        <title>Recommendation 9</title>
        <p><bold>PTH levels should be kept at two to three times the upper limit of the normal range in end-stage renal disease (evidence).</bold> Grossly elevated PTH concentrations (&gt;four times the upper normal range) in the presence of normal or high serum calcium and high alkaline phosphatase are almost always associated with high-turnover bone disease [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR57">57</xref>]. The exception is intermittent therapy with high-dose active vitamin D metabolites, because 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> directly inhibits osteoblastic function and proliferation. Hyperphosphatemia can occur in hyperparathyroid bone disease because of excessive bone resorption.</p>
        <p>However, in pediatric dialysis patients low and even normal levels of PTH are reported to be associated with low turnover bone disease [<xref ref-type="bibr" rid="CR57">57</xref>]. A PTH concentration higher than in healthy subjects is needed to stimulate bone turnover due to resistance of the skeleton to PTH in advanced renal failure. If PTH falls into the (low) normal range, the risk of hypercalcemia increases [<xref ref-type="bibr" rid="CR58">58</xref>]. Hyperphosphatemia and hypercalcemia can develop in low turnover bone disease because the skeleton is unable to take up enough phosphate and calcium. Low bone turnover or adynamic bone disease is increasingly observed in adult [<xref ref-type="bibr" rid="CR59">59</xref>] as well as in pediatric PD patients [<xref ref-type="bibr" rid="CR56">56</xref>]. Risk factors for adynamic bone disease are high calcium intake (Ca-containing phosphate binders), therapy with high doses of active vitamin D metabolites, peritoneal dialysis using dialysis fluid with high calcium content and age (adolescents after the growth spurt). Biochemically, hypercalcemia and/or PTH levels within or below the normal range are indicative of low turnover bone disease [<xref ref-type="bibr" rid="CR56">56</xref>, <xref ref-type="bibr" rid="CR58">58</xref>], which may adversely affect growth in dialysed children [<xref ref-type="bibr" rid="CR60">60</xref>]. Therefore, active vitamin D therapy should be reduced or stopped if PTH falls below the low normal range [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR59">59</xref>, <xref ref-type="bibr" rid="CR61">61</xref>]. If PTH remains below normal despite normal calcium and phosphate levels, the dialysate should be changed to low calcium solutions (1.0 or 1.25&#xA0;mmol/l) to stimulate PTH secretion [<xref ref-type="bibr" rid="CR61">61</xref>], if this is not already used as the standard solution [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
      </sec>
      <sec id="Sec13">
        <title>Recommendation 10</title>
        <p><bold>If PTH is elevated in children with CRF or if PTH is elevated more than two to three times normal in the presence of Pi &lt;2&#xA0;mmol/l in dialyzed children, active vitamin D metabolites should be administered orally (evidence).</bold> Treatment with active vitamin D metabolites results in biochemical and/or histological improvement in patients with high-turnover bone disease. Doses of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> or 1&#x3B1;-(OH) vitamin D<sub>3</sub> usually range from 0.1&#xA0;&#xB5;g/day to 0.75&#xA0;&#xB5;g/day, with a starting dose of 20&#x2013;40&#xA0;ng/kg. High doses often induce hypercalcemia, necessitating the reduction or discontinuation of vitamin D therapy (see hypercalcemia).</p>
        <p>As to the mode of administration of the active vitamin D metabolites, intravenous or oral therapy, have the same efficacy [<xref ref-type="bibr" rid="CR63">63</xref>]. Therefore, the oral route should be preferred in children on dialysis. Doses should be given in the evening, because fewer episodes of hypercalcemia have been reported compared to taking the vitamin D metabolites in the morning [<xref ref-type="bibr" rid="CR64">64</xref>]. Intermittent therapy was shown to be effective to suppress elevated PTH serum levels [<xref ref-type="bibr" rid="CR59">59</xref>]. However, recent data indicate that large intermittent 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> doses adversely affect bone turnover [<xref ref-type="bibr" rid="CR57">57</xref>, <xref ref-type="bibr" rid="CR61">61</xref>, <xref ref-type="bibr" rid="CR65">65</xref>] and chondrocyte activity [<xref ref-type="bibr" rid="CR66">66</xref>] resulting in low turnover bone disease and in reduced growth [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>, <xref ref-type="bibr" rid="CR67">67</xref>, <xref ref-type="bibr" rid="CR68">68</xref>]. In addition, episodes of hypercalcemia occur with similar frequency with the intermittent or oral administration of vitamin D metabolites [<xref ref-type="bibr" rid="CR63">63</xref>, <xref ref-type="bibr" rid="CR69">69</xref>]; furthermore, the intermittent mode of administration was not shown to be more effective in suppressing PTH levels in adult [<xref ref-type="bibr" rid="CR70">70</xref>] and pediatric [<xref ref-type="bibr" rid="CR63">63</xref>] patients in prospective, randomized trials. For the above mentioned reasons, intermittent high-dose vitamin D therapy should be avoided in pediatric patients.</p>
        <p>Three newer vitamin D analogs, so called &#x201C;non-hypercalcemic&#x201D; vitamin D analogs (doxercalciferol, paricalcitol and 22-oxa-calciferol), have been introduced in clinical use in adult patients with secondary hyperparathyroidism due to CRF. Despite their ability to induce less hypercalcemia in animal experiments, only one clinical study with a head-to-head comparison of the new vitamin D analogue (paricalcitol) is available demonstrating a borderline reduction of hypercalcemia or a decrease in calcium phosphorus product [<xref ref-type="bibr" rid="CR71">71</xref>]. No data are available for their use in children.</p>
        <p>Agents that specifically enhance the sensitivity of the calcium-sensing receptor, called calcimimetics, used in combination with active vitamin D metabolites in adult dialysis patients resulted in a persistent decrease of PTH levels without elevated calcium phosphorus product [<xref ref-type="bibr" rid="CR72">72</xref>]. If plasma Ca or Pi is high in the presence of elevated PTH, the calcimimetics may become first choice. However, no data for pediatric patients are available.</p>
      </sec>
      <sec id="Sec14">
        <title>Recommendation 11</title>
        <p><bold>Treatment with growth hormone should not be started in the presence of severe hyperparathyroid bone disease.</bold> It is well established that the uremic growth retardation is at least in part due to disturbed pulsatile secretion of growth hormone as well as a peripheral growth hormone resistance [<xref ref-type="bibr" rid="CR73">73</xref>]. After correction of metabolic acidosis and normalization of caloric intake, administration of recombinant human growth hormone increases growth velocity resulting in catch-up growth and in improved final height [<xref ref-type="bibr" rid="CR74">74</xref>]. Growth hormone directly stimulates growth cartilage proliferation and metabolism and osteoblast activity [<xref ref-type="bibr" rid="CR75">75</xref>, <xref ref-type="bibr" rid="CR76">76</xref>]. This growth promoting effect of GH was suspected to increase the metaphyseal instability induced by severe hyperparathyroidism. In hyperparathyroid bone disease, i.e., osteitis fibrosa, a fibrous layer is formed at the metaphyseal junction of the growth plate with the bone tissue. This can lead to epiphyseal slipping resulting in gross deformities of the affected long bones [<xref ref-type="bibr" rid="CR77">77</xref>]. Therefore, parathyroid hormone, as well as calcium and phosphate levels, should be treated towards the recommended normal ranges prior to administration of GH. However, in a recent prospective study, no increased frequency of epiphyseal slipping associated with the use of growth hormone was reported [<xref ref-type="bibr" rid="CR78">78</xref>]. After the start of GH administration, an increase of PTH levels was observed [<xref ref-type="bibr" rid="CR79">79</xref>, <xref ref-type="bibr" rid="CR80">80</xref>].</p>
      </sec>
      <sec id="Sec15">
        <title>Recommendation 12</title>
        <p><bold>In case of hypercalcemia, active vitamin D metabolites and calcium-containing phosphate binders should be stopped and dialysate changed to low calcium solutions (evidence).</bold> Hypercalcemia and elevated calcium phosphorus product (&gt;5.0&#xA0;mmol<sup>2</sup>/l<sup>2</sup>) should be corrected promptly (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). Vitamin D metabolites should be discontinued and in case of persisting hypercalcemia the dialysate calcium decreased to low calcium dialysate. Laboratory values should be controlled weekly until improvement is seen. One exception is hypercalcemia due to severe hyperparathyroidism and high-turnover bone disease. In addition, in patients with residual renal function, loop diuretics, i.e., furosemide may increase calcium excretion. If hypercalcemia is not corrected despite the discontinuation of active vitamin D metabolites, calcium-containing phosphate binders should be replaced by calcium-free phosphate binders to reduce the calcium load. Hypercalcemia is reported in up to 25% of patients taking calcium-containing phosphate binders ([<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], see recommendation 6).<fig id="Fig1"><label> Fig.&#xA0;1</label><caption><p> Clinical algorithm for treatment of elevated calcium phosphorus product in children with CRF.<italic> Ca-cont</italic> calcium containing;<italic> Ca-free</italic> calcium-free;<italic> phos-binder</italic> phosphate binder;<italic> vit D</italic> vitamin D;<italic> ADBD</italic> adynamic bone disease</p></caption><graphic position="anchor" xlink:href="s00467-005-2082-7flb1"/></fig></p>
      </sec>
      <sec id="Sec16">
        <title>Recommendation 13</title>
        <p>The calcium phosphorus product should be kept within the normal range, at least below 5.0&#xA0;mmol<sup>2</sup>/l<sup>2</sup> (60&#xA0;mg<sup>2</sup>/dl<sup>2</sup>) (evidence). One of the risk factors for cardiovascular morbidity was shown to be an elevated calcium phosphorus product above 5.0&#xA0;mmol<sup>2</sup>/l<sup>2</sup> (see also recommendation 2). If the calcium phosphorus product is elevated above this level, phosphate and/or calcium levels should be reduced. This may be achieved by an increase in phosphate binders, reduction/stopping of active vitamin D metabolites and use of low calcium (Ca<sup>++</sup> 1.0&#x2013;1.25&#xA0;mmol/l) dialysate.</p>
      </sec>
      <sec id="Sec17">
        <title>Recommendation 14</title>
        <p>Parathyroidectomy has to be considered in case of severe, therapy-refractory hyperparathyroidism with radiological signs in combination with hypercalcemia and/or elevated calcium phosphorus product (evidence). Severe hyperparathyroidism may no longer react to even high doses of 1,25(OH)<sub>2</sub> vitamin D<sub>3</sub> and reduction of phosphate levels. The clinical observations in adults show that patients with at least one parathyroid gland larger than 0.5&#xA0;cm<sup>3</sup> or 1.0&#xA0;cm in diameter usually do not respond to active vitamin D metabolites [<xref ref-type="bibr" rid="CR81">81</xref>, <xref ref-type="bibr" rid="CR82">82</xref>]. Therefore, persisting grossly elevated PTH levels in the presence of high-dose active vitamin D metabolites, radiological signs of hyperparathyroidism on wrist X-ray and/or high serum calcium and normal phosphate and/or elevated calcium phosphorus product indicate the need for surgical parathyroidectomy. Medical parathyroidectomy by alcohol injection was described in adult patients [<xref ref-type="bibr" rid="CR83">83</xref>], but to our knowledge not in pediatric patients. Parathyroid hormone stimulates bone turnover and regulates calcium homeostasis, both of which are of utmost importance in the growing skeleton. Therefore, subtotal parathyroidectomy or autotransplantation of parathyroid tissue is recommended in children or adolescents, avoiding hypoparathyroidism ([<xref ref-type="bibr" rid="CR84">84</xref>], review). However, these procedures carry the risk of recurrence of severe parathyroid tissue hyperplasia. The use of the new calcimimetic agents [<xref ref-type="bibr" rid="CR85">85</xref>] may help to prevent the most severe hyperparathyroidism and therefore modify the approach to that condition.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <citation citation-type="other">Goodman WG, Goldin J, Kuizon BD, Yoon C, Gales B, Sider D, Wang Y, Chung J, Emerick A, Greaser L, Elashoff RM, Salusky IB (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med. 342:1478&#x2013;1483</citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Oh</surname>
            </name>
          </person-group>
          <source>Circulation</source>
          <year>2002</year>
          <volume>106</volume>
          <fpage>100</fpage>
          <pub-id pub-id-type="doi">10.1161/01.CIR.0000020222.63035.C0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Oh J, Wunsch R, Turzer M, Bahner M, Raggi P, Querfeld U, Mehls O, Schaefer F (2002) Advanced coronary and carotid arteriopathy in young adults with childhood-onset chronic renal failure. Circulation 106:100&#x2013;105 <pub-id pub-id-type="pmid">12093777</pub-id></citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Watson</surname>
            </name>
          </person-group>
          <source>Perit Dial Int</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>240</fpage>
        </citation>
        <citation citation-type="display-unstructured">Watson AR, Gartland C (2001) European Paediatric Peritoneal Dialysis Working Group Guidelines by an Ad Hoc European Committee for Elective Chronic Peritoneal Dialysis in Pediatric Patients. Perit Dial Int 21:240&#x2013;244 <pub-id pub-id-type="pmid">11475338</pub-id></citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroder</surname>
            </name>
          </person-group>
          <source>Perit Dial Int</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>568</fpage>
        </citation>
        <citation citation-type="display-unstructured">Schr&#xF6;der CH, European Paediatric Peritoneal Dialysis Working Group (2001) The choice of dialysis solutions in pediatric chronic peritoneal dialysis: guidelines by an ad hoc European committee. Perit Dial Int 21:568&#x2013;574 <pub-id pub-id-type="pmid">11783765</pub-id></citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischbach</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>2002</year>
          <volume>17</volume>
          <fpage>380</fpage>
          <pub-id pub-id-type="doi">10.1093/ndt/17.3.380</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fischbach M, Stefanidis CJ, Watson AR, European Paediatric Peritoneal Dialysis Working Group (2002) Guidelines by an ad hoc European committee on adequacy of the paediatric peritoneal dialysis prescription. Nephrol Dial Transplant 17:380&#x2013;385 <pub-id pub-id-type="pmid">11865081</pub-id></citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schroder</surname>
            </name>
          </person-group>
          <source>Perit Dial Int</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>568</fpage>
        </citation>
        <citation citation-type="display-unstructured">Schr&#xF6;der CH, Watson AR on behalf of the European Paediatric Peritoneal Working Group (2001) The choice of dialysis solutions in chronic peritoneal dialysis: guidelines by an ad hoc European committee. Perit Dial Int 21:568&#x2013;574 <pub-id pub-id-type="pmid">11783765</pub-id></citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Blind</surname>
            </name>
          </person-group>
          <source>Clin Chem</source>
          <year>1987</year>
          <volume>33</volume>
          <fpage>1376</fpage>
        </citation>
        <citation citation-type="display-unstructured">Blind E, Schmidt-Gayk H, Armbruster FP, Stadler A (1987) Measurement of intact human parathyrin by an extracting two-site immunoradiometric assay. Clin Chem 33:1376&#x2013;1381 <pub-id pub-id-type="pmid">3608156</pub-id></citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Gao</surname>
            </name>
          </person-group>
          <source>J Bone Miner Res</source>
          <year>2001</year>
          <volume>16</volume>
          <fpage>605</fpage>
        </citation>
        <citation citation-type="display-unstructured">Gao P, Scheibel S, D&#x2019;Amour P, John MR, Rao SD, Schmidt-Gayk H, Cantor TL (2001) Development of a novel immunoradiometric assay exclusively for biologically active whole parathyroid hormone 1&#x2013;84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 16:605&#x2013;614 <pub-id pub-id-type="pmid">11315988</pub-id></citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reichel</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>759</fpage>
          <pub-id pub-id-type="doi">10.1093/ndt/gfg144</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Reichel H, Esser A, Roth HJ, Schmidt-Gayk H (2003) Influence of PTH assay methodology on differential diagnosis of renal bone disease. Nephrol Dial Transplant 18:759&#x2013;768 <pub-id pub-id-type="pmid">12637646</pub-id></citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waller</surname>
            </name>
          </person-group>
          <source>Parathyroid hormone and its fragments in children with chronic renal failure Pediatr Nephrol</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>1242</fpage>
        </citation>
        <citation citation-type="display-unstructured">Waller S, Reynolds A, Ridout D, Cantor T, Gao P, Rees L (2003) Parathyroid hormone and its fragments in children with chronic renal failure Pediatr Nephrol 18:1242&#x2013;1248 </citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salusky</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>1801</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00915.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Salusky IB, Goodman WG, Kuizon BD, Lavigne JR, Zahranik RJ, Gales B, Wang HJ, Elashoff RM, Juppner H (2003) Similar predictive value of bone turnover using first- and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 63:1801&#x2013;1808 <pub-id pub-id-type="pmid">12675856</pub-id></citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <citation citation-type="other">Martin KJ, Olgaard K, Coburn JW, Coen GM, Fukagawa M, Langman C, Malluche HH, McCarthy JT, Massry SG, Mehls O, Salusky IB, Silver JM, Smogorzewski MT, Slatopolsky EM, McCann L Bone Turnover Work Group (2004) Diagnosis, assessment, and treatment of bone turnover abnormalities in renal osteodystrophy Am J Kidney Dis. 43:558&#x2013;565</citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lefebvre</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1989</year>
          <volume>36</volume>
          <fpage>1112</fpage>
        </citation>
        <citation citation-type="display-unstructured">Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C (1989) Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 36:1112&#x2013;1118 <pub-id pub-id-type="pmid">2557481</pub-id></citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Carbajo</surname>
            </name>
          </person-group>
          <source>J Am Soc Nephrol</source>
          <year>2001</year>
          <volume>12</volume>
          <fpage>1228</fpage>
        </citation>
        <citation citation-type="display-unstructured">Carbajo E, Lopez JM, Santos F, Ordonez FA, Nino P, Rodriguez J (2001) Histologic and dynamic change induced by chronic metabolic acidosis in the rat growth plate. J Am Soc Nephrol 12:1228&#x2013;1234 <pub-id pub-id-type="pmid">11373346</pub-id></citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kalhoff</surname>
            </name>
          </person-group>
          <source>Eur J Nutr</source>
          <year>2001</year>
          <volume>40</volume>
          <fpage>221</fpage>
          <pub-id pub-id-type="doi">10.1007/s394-001-8349-y</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kalhoff H, Manz F (2001) Nutrition, acid-base status and growth in early childhood. Eur J Nutr 40:221&#x2013;230 <pub-id pub-id-type="pmid">11842947</pub-id></citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kovacic</surname>
            </name>
          </person-group>
          <source>Am J Nephrol</source>
          <year>2003</year>
          <volume>23</volume>
          <fpage>158</fpage>
          <pub-id pub-id-type="doi">10.1159/000070205</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kovacic V, Roguljic L, Kovacic V (2003) Metabolic acidosis of chronically hemodialyzed patients. Am J Nephrol 23:158&#x2013;164 <pub-id pub-id-type="pmid">12649614</pub-id></citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Feriani</surname>
            </name>
          </person-group>
          <source>Perit Dial Int</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>17</fpage>
        </citation>
        <citation citation-type="display-unstructured">Feriani M, Carobi C, La Greca G, Buoncristiani U, Passlick-Deetjen J (1997) Clinical experience with a 39&#xA0;mmol/l bicarbonate-buffered peritoneal dialysis solution. Perit Dial Int 17:17&#x2013;21 <pub-id pub-id-type="pmid">9068017</pub-id></citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coburn</surname>
            </name>
          </person-group>
          <source>Am J Kidney Dis</source>
          <year>1991</year>
          <volume>17</volume>
          <fpage>708</fpage>
        </citation>
        <citation citation-type="display-unstructured">Coburn JW, Mischel MG, Goodman WG, Salusky IB (1991) Calcium citrate markedly enhances aluminum absorption from aluminum hydroxide. Am J Kidney Dis 17:708&#x2013;711 <pub-id pub-id-type="pmid">2042654</pub-id></citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>K</surname>
            </name>
          </person-group>
          <source>Clinical practice guidelines for bone metabolism and disease in chronic kidney disease</source>
          <year>2004</year>
          <volume>Epub</volume>
          <fpage>www</fpage>
        </citation>
        <citation citation-type="display-unstructured">K/DOQI (2004) Clinical practice guidelines for bone metabolism and disease in chronic kidney disease Epub: www.kidney.org/professionals/kdoqi/guidelines_bone/index.htm </citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Norman</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>833</fpage>
          <pub-id pub-id-type="doi">10.1007/s004670000318</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Norman LJ, Coleman JE, Macdonald I, Tomsett A, Watson AR (2000) Nutrition and growth in relation to severity of renal disease in children. Pediatr Nephrol 14:833&#x2013;836 <pub-id pub-id-type="pmid">10955939</pub-id></citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Slatopolsky</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1973</year>
          <volume>4</volume>
          <fpage>141</fpage>
        </citation>
        <citation citation-type="display-unstructured">Slatopolsky E, Bricker NS (1973) The role of phosphorus restriction in the prevention of secondary hyperparathyroidism in chronic renal disease. Kidney Int 4:141&#x2013;145 <pub-id pub-id-type="pmid">4355426</pub-id></citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kilav</surname>
            </name>
          </person-group>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>96</volume>
          <fpage>327</fpage>
        </citation>
        <citation citation-type="display-unstructured">Kilav R, Silver J, Naveh-Many T (1995) Parathyroid hormone gene expression in hypophosphatemic rats. J Clin Invest 96:327&#x2013;333 <pub-id pub-id-type="pmid">7615802</pub-id></citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Naveh-Many</surname>
            </name>
          </person-group>
          <source>J Clin Invest</source>
          <year>1995</year>
          <volume>96</volume>
          <fpage>1786</fpage>
        </citation>
        <citation citation-type="display-unstructured">Naveh-Many T, Rahamimov R, Livni N, Silver J (1995) Parathyroid cell proliferation in normal and chronic renal failure rats. The effects of calcium, phosphate, and vitamin D. J Clin Invest 96:1786&#x2013;1793 <pub-id pub-id-type="pmid">7560070</pub-id></citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Almaden</surname>
            </name>
          </person-group>
          <source>J Bone Miner Res</source>
          <year>1996</year>
          <volume>11</volume>
          <fpage>970</fpage>
        </citation>
        <citation citation-type="display-unstructured">Almaden Y, Canalejo A, Hernandez A, Ballesteros E, Garcia-Navarro S, Torres A, Rodriguez M (1996) Direct effect of phosphorus on PTH secretion from whole rat parathyroid glands in vitro. J Bone Miner Res 11:970&#x2013;976 <pub-id pub-id-type="pmid">8797118</pub-id></citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Portale</surname>
            </name>
          </person-group>
          <source>J Clin Invest</source>
          <year>1984</year>
          <volume>73</volume>
          <fpage>1580</fpage>
        </citation>
        <citation citation-type="display-unstructured">Portale AA, Booth BE, Halloran BP, Morris RC Jr (1984) Effect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 73:1580&#x2013;1589 <pub-id pub-id-type="pmid">6547151</pub-id></citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <citation citation-type="other">Silver J, Yalcindag C, Sela-Brown A, Kilav R, Naveh-Many T (1999) Regulation of the parathyroid hormone gene by vitamin D, calcium and phosphate. Kidney Int [Suppl] 73:S2&#x2013;7</citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Yi</surname>
            </name>
          </person-group>
          <source>Nephron</source>
          <year>1995</year>
          <volume>70</volume>
          <fpage>242</fpage>
        </citation>
        <citation citation-type="display-unstructured">Yi H, Fukagawa M, Yamato H, Kumagai M, Watanabe T, Kurokawa K (1995) Prevention of enhanced parathyroid hormone secretion, synthesis and hyperplasia by mild dietary phosphorus restriction in early chronic renal failure in rats: possible direct role of phosphorus. Nephron 70:242&#x2013;248 <pub-id pub-id-type="pmid">7566311</pub-id></citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Milliner</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1990</year>
          <volume>38</volume>
          <fpage>931</fpage>
        </citation>
        <citation citation-type="display-unstructured">Milliner DS, Zinsmeister AR, Lieberman E, Landing B (1990) Soft tissue calcification in pediatric patients with end-stage renal disease. Kidney Int 38:931&#x2013;936 <pub-id pub-id-type="pmid">2266678</pub-id></citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Block</surname>
            </name>
          </person-group>
          <source>Am J Kidney Dis</source>
          <year>1998</year>
          <volume>31</volume>
          <fpage>607</fpage>
        </citation>
        <citation citation-type="display-unstructured">Block GA, Hulbert-Shearon TE, Levin NW, Port FK (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 31:607&#x2013;617 <pub-id pub-id-type="pmid">9531176</pub-id></citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Huting</surname>
            </name>
          </person-group>
          <source>Chest</source>
          <year>1994</year>
          <volume>105</volume>
          <fpage>383</fpage>
        </citation>
        <citation citation-type="display-unstructured">Huting J (1994) Mitral valve calcification as an index of left ventricular dysfunction in patients with end-stage renal disease on peritoneal dialysis. Chest 105:383&#x2013;388 <pub-id pub-id-type="pmid">8306733</pub-id></citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ribeiro</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>1998</year>
          <volume>13</volume>
          <fpage>2037</fpage>
          <pub-id pub-id-type="doi">10.1093/ndt/13.8.2037</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F (1998) Cardiac valve calcification in haemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 13:2037&#x2013;2040 <pub-id pub-id-type="pmid">9719161</pub-id></citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Moe</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>2002</year>
          <volume>61</volume>
          <fpage>638</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.2002.00170.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Moe SM, O&#x2019;Neill KD, Duan D, Ahmed S, Chen NX, Leapman SB, Fineberg N, Kopecky K (2002) Medial artery calcification in ESRD patients is associated with deposition of bone matrix proteins. Kidney Int 61:638&#x2013;647 <pub-id pub-id-type="pmid">11849407</pub-id></citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <citation citation-type="other">Shioi A, Taniwaki H, Jono S, Okuno Y, Koyama H, Mori K, Nishizawa Y (2001) Monckeberg&#x2019;s medial sclerosis and inorganic phosphate in uremia. Am J Kidney Dis 38 [Suppl 1]:S47&#x2013;49</citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Amann</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>1296</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00864.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Amann K, Tornig J, Kugel B, Gross ML, Tyralla K, El-Shakmak A, Szabo A, Ritz E (2003) Hyperphosphatemia aggravates cardiac fibrosis and microvascular disease in experimental uremia. Kidney Int 63:1296&#x2013;1301 <pub-id pub-id-type="pmid">12631346</pub-id></citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Coleman</surname>
            </name>
          </person-group>
          <source>Perit Dial Int</source>
          <year>2001</year>
          <volume>21</volume>
          <fpage>323</fpage>
        </citation>
        <citation citation-type="display-unstructured">Coleman JE, Edefonti A, Watson AR on behalf of the European Pediatric Peritoneal Working Group (2001) Guidelines by an ad hoc European committee on the assessment of growth and nutritional status in children on chronic peritoneal dialysis. Perit Dial Int 21:323 (www.ispd.org.guidelines) </citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schaefer</surname>
            </name>
          </person-group>
          <source>Adv Perit Dial</source>
          <year>1992</year>
          <volume>8</volume>
          <fpage>410</fpage>
        </citation>
        <citation citation-type="display-unstructured">Schaefer F, Langenbeck D, Heckert KH, Scharer K, Mehls O (1992) Evaluation of peritoneal solute transfer by the peritoneal equilibration test in children. Adv Perit Dial 8:410&#x2013;415 <pub-id pub-id-type="pmid">1361835</pub-id></citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischbach</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>1997</year>
          <volume>11</volume>
          <fpage>193</fpage>
          <pub-id pub-id-type="doi">10.1007/s004670050258</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fischbach M, Boudailliez B, Foulard M (1997) Phosphate end dialysis value: a misleading parameter of hemodialysis efficiency. Pediatr Nephrol 11:193&#x2013;195 <pub-id pub-id-type="pmid">9090662</pub-id></citation>
      </ref>
      <ref id="CR38">
        <label>38.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maasrani</surname>
            </name>
          </person-group>
          <source>Int J Artif Organs</source>
          <year>1995</year>
          <volume>18</volume>
          <fpage>122</fpage>
        </citation>
        <citation citation-type="display-unstructured">Maasrani M, Jaffrin MY, Fischbach M, Boudailliez B (1995) Urea creatinine and phosphate kinetic modelling during dialysis: application to pediatric hemodialysis. Int J Artif Organs 18:122&#x2013;129 <pub-id pub-id-type="pmid">7499014</pub-id></citation>
      </ref>
      <ref id="CR39">
        <label>39.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Bell</surname>
            </name>
          </person-group>
          <source>Hemodial Int</source>
          <year>2003</year>
          <volume>7</volume>
          <fpage>290</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1492-7535.2003.00052.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Bell L, Espinosa P (2003) Intensive in center hemodialysis for children: a case for longer dialysis duration. Hemodial Int 7:290&#x2013;295 </citation>
      </ref>
      <ref id="CR40">
        <label>40.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Maduell</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>2003</year>
          <volume>64</volume>
          <fpage>305</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00043.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Maduell F, Navarro V, Torregrosa E, Rius A, Dicenta F, Cruz MC, Ferrero JA (2003) Change from three times a week on line hemodiafiltration to short daily on line hemodiafiltration. Kidney Int 64:305&#x2013;313 <pub-id pub-id-type="pmid">12787423</pub-id></citation>
      </ref>
      <ref id="CR41">
        <label>41.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Traeger</surname>
            </name>
          </person-group>
          <source>Dialysis Transplant</source>
          <year>2001</year>
          <volume>30</volume>
          <fpage>76</fpage>
        </citation>
        <citation citation-type="display-unstructured">Traeger S, Galland R, Arkouche W, Delawari E, Fouque D (2001) Short daily hemodialysis: a 4-year experience. Dialysis Transplant 30:76&#x2013;86 </citation>
      </ref>
      <ref id="CR42">
        <label>42.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischbach</surname>
            </name>
          </person-group>
          <source>Nephron</source>
          <year>1992</year>
          <volume>62</volume>
          <fpage>155</fpage>
        </citation>
        <citation citation-type="display-unstructured">Fischbach M, Hamel G, Simeoni U, Geisert J (1992) Phosphate dialytic removal: enhancement of phosphate cellular clearance by biofiltration (with acetate free buffer dialysate). Nephron 62:155&#x2013;160 <pub-id pub-id-type="pmid">1436307</pub-id></citation>
      </ref>
      <ref id="CR43">
        <label>43.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischbach</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>1998</year>
          <volume>12</volume>
          <fpage>60</fpage>
          <pub-id pub-id-type="doi">10.1007/s004670050404</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fischbach M, Terzic J, Cousandier E, Hamel G, Geisert J (1998) Glucose charged dialysate for children on hemodialysis: acute dialytic changes. Pediatr Nephrol 12:60&#x2013;62 <pub-id pub-id-type="pmid">9502570</pub-id></citation>
      </ref>
      <ref id="CR44">
        <label>44.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fischbach</surname>
            </name>
          </person-group>
          <source>Daily on line</source>
          <year>2004</year>
          <volume>hemodiafiltration</volume>
          <fpage>a</fpage>
        </citation>
        <citation citation-type="display-unstructured">Fischbach M, Terzic J, Laugel V, Dheu C, Menouer S, Helms P, Livolsi A (2004) Daily on line hemodiafiltration: a pilot experience in children. Nephrol Dial Transpl (submitted) </citation>
      </ref>
      <ref id="CR45">
        <label>45.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schiller</surname>
            </name>
          </person-group>
          <source>New Engl J Med</source>
          <year>1989</year>
          <volume>27</volume>
          <fpage>1110</fpage>
        </citation>
        <citation citation-type="display-unstructured">Schiller LR, Santa Ana CA, Sheikh MS, Emmett M, Fordtran JS (1989) Effect of the time of administration of calcium acetate on phosphorus binding. New Engl J Med 27:1110&#x2013;1113 <pub-id pub-id-type="pmid">2710173</pub-id></citation>
      </ref>
      <ref id="CR46">
        <label>46.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wallot</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>1996</year>
          <volume>10</volume>
          <fpage>625</fpage>
          <pub-id pub-id-type="doi">10.1007/s004670050175</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wallot M, Bonzel KE, Winter A, Georger B, Lettgen B, Bald M (1996) Calcium acetate versus calcium carbonate as oral phosphate binder in pediatric and adolescent hemodialysis patients. Pediatr Nephrol 10:625&#x2013;630 <pub-id pub-id-type="pmid">8897570</pub-id></citation>
      </ref>
      <ref id="CR47">
        <label>47.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pflanz</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>1994</year>
          <volume>9</volume>
          <fpage>1121</fpage>
        </citation>
        <citation citation-type="display-unstructured">Pflanz S, Henderson IS, McElduff N, Jones MC (1994) Calcium acetate versus calcium carbonate as phosphate-binding agents in chronic haemodialysis. Nephrol Dial Transplant 9:1121&#x2013;1124 <pub-id pub-id-type="pmid">7800211</pub-id></citation>
      </ref>
      <ref id="CR48">
        <label>48.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lowrie</surname>
            </name>
          </person-group>
          <source>Am J Kidney Dis</source>
          <year>1990</year>
          <volume>15</volume>
          <fpage>458</fpage>
        </citation>
        <citation citation-type="display-unstructured">Lowrie EG, Lew NL (1990) Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 15:458&#x2013;482 <pub-id pub-id-type="pmid">2333868</pub-id></citation>
      </ref>
      <ref id="CR49">
        <label>49.</label>
        <citation citation-type="other">D&#x2019;Haese PC, Spasovski GB, Sikole A, Hutchison A, Freemont TJ, Sulkova S, Swanepoel C, Pejanovic S, Djukanovic L, Balducci A, Coen G, Sulowicz W, Ferreira A, Torres A, Curic S, Popovic M, Dimkovic N, De Broe ME (2003) A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int [Suppl] 85:S73&#x2013;78</citation>
      </ref>
      <ref id="CR50">
        <label>50.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fernandez-Gavarron</surname>
            </name>
          </person-group>
          <source>Bone Miner</source>
          <year>1988</year>
          <volume>3</volume>
          <fpage>283</fpage>
        </citation>
        <citation citation-type="display-unstructured">Fernandez-Gavarron F, Huque T, Rabinowitz JL, Brand JG (1988) Incorporation of 140-lanthanum into bones, teeth and hydroxyapatite. Bone Miner 3:283&#x2013;291 <pub-id pub-id-type="pmid">3228613</pub-id></citation>
      </ref>
      <ref id="CR51">
        <label>51.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Reichel</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>1991</year>
          <volume>6</volume>
          <fpage>162</fpage>
        </citation>
        <citation citation-type="display-unstructured">Reichel H, Deibert B, Schmidt-Gayk H, Ritz E (1991) Calcium metabolism in early chronic renal failure: implications for the pathogenesis of hyperparathyroidism. Nephrol Dial Transplant 6:162&#x2013;169 <pub-id pub-id-type="pmid">1866044</pub-id></citation>
      </ref>
      <ref id="CR52">
        <label>52.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dusso</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1988</year>
          <volume>34</volume>
          <fpage>368</fpage>
        </citation>
        <citation citation-type="display-unstructured">Dusso A, Lopez-Hilker S, Rapp N, Slatopolsky E (1988) Extra-renal production of calcitriol in chronic renal failure. Kidney Int 34:368&#x2013;375 <pub-id pub-id-type="pmid">3172645</pub-id></citation>
      </ref>
      <ref id="CR53">
        <label>53.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van</surname>
            </name>
          </person-group>
          <source>Lancet</source>
          <year>1995</year>
          <volume>346</volume>
          <fpage>207</fpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(95)91266-5</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Van der Wielen RP, Lowik MR, van den Berg H, de Groot LC, Haller J, Moreiras O, van Staveren WA (1995) Serum vitamin D concentrations among elderly people in Europe. Lancet 346:207&#x2013;210 <pub-id pub-id-type="pmid">7616799</pub-id></citation>
      </ref>
      <ref id="CR54">
        <label>54.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Birge</surname>
            </name>
          </person-group>
          <source>J Clin Invest</source>
          <year>1975</year>
          <volume>56</volume>
          <fpage>1100</fpage>
        </citation>
        <citation citation-type="display-unstructured">Birge SJ, Haddad JG (1975) 25-hydroxycholecalciferol stimulation of muscle metabolism. J Clin Invest 56:1100&#x2013;1107 <pub-id pub-id-type="pmid">1184737</pub-id></citation>
      </ref>
      <ref id="CR55">
        <label>55.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ritz</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>1995</year>
          <volume>10</volume>
          <fpage>2228</fpage>
        </citation>
        <citation citation-type="display-unstructured">Ritz E, K&#xFC;ster S, Schmidt-Gayk H, Stein G, Scholz C, Kraatz G, Heidland A (1995) Low-dose calcitriol prevents the rise in 1,84-iPTH without affecting serum calcium and phosphate in patients with moderate renal failure (prospective placebo-controlled multicentre trial). Nephrol Dial Transplant 10:2228&#x2013;2234 <pub-id pub-id-type="pmid">8808216</pub-id></citation>
      </ref>
      <ref id="CR56">
        <label>56.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waller</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>1236</fpage>
          <pub-id pub-id-type="doi">10.1007/s00467-003-1284-0</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Waller S, Ledermann S, Trompeter R, van&#x2019;t Hoff W, Ridout D, Rees L (2003) Catch-up growth with normal parathyroid hormone levels in chronic renal failure. Pediatr Nephrol 18:1236&#x2013;1241 <pub-id pub-id-type="pmid">14586680</pub-id></citation>
      </ref>
      <ref id="CR57">
        <label>57.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Salusky</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1994</year>
          <volume>45</volume>
          <fpage>253</fpage>
        </citation>
        <citation citation-type="display-unstructured">Salusky IB, Ramirez JA, Oppenheim W, Gales B, Segre GV, Goodman WG (1994) Biochemical markers of renal osteodystrophy in pediatric patients undergoing CAPD/CCPD. Kidney Int 45:253&#x2013;258 <pub-id pub-id-type="pmid">8127016</pub-id></citation>
      </ref>
      <ref id="CR58">
        <label>58.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Piscitelli</surname>
            </name>
          </person-group>
          <source>J Pediatr Endocrinol Metab</source>
          <year>1999</year>
          <volume>12</volume>
          <fpage>879</fpage>
        </citation>
        <citation citation-type="display-unstructured">Piscitelli J, Cabansag MR, Silverstein DM (1999) Correlation among markers of renal osteodystrophy in pediatric hemodialysis patients. J Pediatr Endocrinol Metab 12:879&#x2013;886 <pub-id pub-id-type="pmid">10614547</pub-id></citation>
      </ref>
      <ref id="CR59">
        <label>59.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klaus</surname>
            </name>
          </person-group>
          <source>Lancet</source>
          <year>1991</year>
          <volume>337</volume>
          <fpage>800</fpage>
          <pub-id pub-id-type="doi">10.1016/0140-6736(91)91429-X</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Klaus G, Mehls O, Hinderer J, Ritz E (1991) Is intermittent oral calcitriol safe and effective in renal secondary hyperparathyroidism? Lancet 337:800&#x2013;801 <pub-id pub-id-type="pmid">1672430</pub-id></citation>
      </ref>
      <ref id="CR60">
        <label>60.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ballanti</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>1996</year>
          <volume>11</volume>
          <fpage>663</fpage>
        </citation>
        <citation citation-type="display-unstructured">Ballanti P, Wedard BM, Bonucci E (1996) Frequency of adynamic bone disease and aluminum storage in Italian uraemic patients&#x2014;retrospective analysis of 1,429 iliac crest biopsies. Nephrol Dial Transplant 11:663&#x2013;667 <pub-id pub-id-type="pmid">8671855</pub-id></citation>
      </ref>
      <ref id="CR61">
        <label>61.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kuizon</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1998</year>
          <volume>53</volume>
          <fpage>205</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.1998.00724.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Kuizon BD, Goodman WG, Juppner H, Boechat I, Nelson P, Gales B, Salusky IB (1998) Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int 53:205&#x2013;211 <pub-id pub-id-type="pmid">9453020</pub-id></citation>
      </ref>
      <ref id="CR62">
        <label>62.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Shigematsu</surname>
            </name>
          </person-group>
          <source>Adv Perit Dial</source>
          <year>1996</year>
          <volume>12</volume>
          <fpage>250</fpage>
        </citation>
        <citation citation-type="display-unstructured">Shigematsu T, Kawaguchi Y, Kubo H, Nakayama M, Kato N, Yamamoto H, Osaka N, Hayakawa H, Ogawa A, Sakai O (1996) Low calcium (1.25&#xA0;mmol/l) dialysate can normalize relative hypoparathyroidism in CAPD patients with low bone turnover. Adv Perit Dial 12:250&#x2013;256 <pub-id pub-id-type="pmid">8865914</pub-id></citation>
      </ref>
      <ref id="CR63">
        <label>63.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ardissino</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>664</fpage>
          <pub-id pub-id-type="doi">10.1007/s004670000365</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ardissino G, Schmitt CP, Testa S, Claris-Appiani A, Mehls O (2000) Calcitriol pulse therapy is not more effective than daily calcitriol therapy in controlling secondary hyperparathyroidism in children with chronic renal failure. European Study Group on Vitamin D in Children with Renal Failure. Pediatr Nephrol 14:664&#x2013;668 <pub-id pub-id-type="pmid">10912539</pub-id></citation>
      </ref>
      <ref id="CR64">
        <label>64.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Tsuruoka</surname>
            </name>
          </person-group>
          <source>Br J Clin Pharmacol</source>
          <year>2003</year>
          <volume>55</volume>
          <fpage>531</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1365-2125.2003.01809.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Tsuruoka S, Wakaumi M, Sugimoto K, Saito T, Fujimura A (2003) Chronotherapy of high-dose active vitamin D3 in haemodialysis patients with secondary hyperparathyroidsm: a repeated dosing study.Br J Clin Pharmacol 55:531&#x2013;537 <pub-id pub-id-type="pmid">12814446</pub-id></citation>
      </ref>
      <ref id="CR65">
        <label>65.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Goodman</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1994</year>
          <volume>46</volume>
          <fpage>1160</fpage>
        </citation>
        <citation citation-type="display-unstructured">Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, Salusky IB (1994) Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int 46:1160&#x2013;1166 <pub-id pub-id-type="pmid">7861712</pub-id></citation>
      </ref>
      <ref id="CR66">
        <label>66.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Klaus</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>1993</year>
          <volume>44</volume>
          <fpage>708</fpage>
        </citation>
        <citation citation-type="display-unstructured">Klaus G, K&#xF6;nig B, H&#xFC;gel U, Ritz E, Mehls O (1993) Intermittent and continuous exposure to 1,25(OH)2D3 have different effects on growth plate chondrocytes in vitro. Kidney Int 44:708&#x2013;715 <pub-id pub-id-type="pmid">8258948</pub-id></citation>
      </ref>
      <ref id="CR67">
        <label>67.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Mehls</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>2000</year>
          <volume>14</volume>
          <fpage>658</fpage>
          <pub-id pub-id-type="doi">10.1007/s004670000346</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Mehls O, Knoller N, Oh J, Wesch H, Wunsche B, Schmitt CP (2000) Daily but not pulse calcitriol therapy improves growth in experimental uremia. Pediatr Nephrol 14:658&#x2013;663 <pub-id pub-id-type="pmid">10912538</pub-id></citation>
      </ref>
      <ref id="CR68">
        <label>68.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Schmitt</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>440</fpage>
        </citation>
        <citation citation-type="display-unstructured">Schmitt CP, Ardissino G, Testa S, Claris-Appiani A, Mehls O (2003) Growth in children with chronic renal failure on intermittent versus daily calcitriol. Pediatr Nephrol 18:440&#x2013;444 <pub-id pub-id-type="pmid">12687466</pub-id></citation>
      </ref>
      <ref id="CR69">
        <label>69.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ardissino</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>2000</year>
          <volume>58</volume>
          <fpage>981</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.2000.00255.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Ardissino G, Schmitt CP, Bianchi ML, Dacco V, Claris-Appiani A, Mehls O (2000) No difference in intestinal strontium absorption after oral or IV calcitriol in children with secondary hyperparathyroidism. The European Study Group on Vitamin D in Children with Renal Failure. Kidney Int 58:981&#x2013;988 <pub-id pub-id-type="pmid">10972662</pub-id></citation>
      </ref>
      <ref id="CR70">
        <label>70.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Herrmann</surname>
            </name>
          </person-group>
          <source>Nephron</source>
          <year>1994</year>
          <volume>67</volume>
          <fpage>48</fpage>
        </citation>
        <citation citation-type="display-unstructured">Herrmann P, Ritz E, Schmidt-Gayk H, Schafer I, Geyer J, Nonnast-Daniel B, Koch KM, Weber U, Horl W, Haas-Worle A (1994) Comparison of intermittent and continuous oral administration of calcitriol in dialysis patients: a randomized prospective trial. Nephron 67:48&#x2013;53 <pub-id pub-id-type="pmid">8052367</pub-id></citation>
      </ref>
      <ref id="CR71">
        <label>71.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sprague</surname>
            </name>
          </person-group>
          <source>Kidney Int</source>
          <year>2003</year>
          <volume>63</volume>
          <fpage>1483</fpage>
          <pub-id pub-id-type="doi">10.1046/j.1523-1755.2003.00878.x</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D (2003) Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 63:1483&#x2013;1490 <pub-id pub-id-type="pmid">12631365</pub-id></citation>
      </ref>
      <ref id="CR72">
        <label>72.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Block</surname>
            </name>
          </person-group>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>1516</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa031633</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drueke TB, Goodman WG (2004) Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med 350:1516&#x2013;1525 <pub-id pub-id-type="pmid">15071126</pub-id></citation>
      </ref>
      <ref id="CR73">
        <label>73.</label>
        <citation citation-type="other">T&#xF6;nshoff B, Blum WF, Mehls O (1997) Derangements of the somatotropic hormone axis in chronic renal failure. Kidney Int [Suppl] 58:S106&#x2013;113</citation>
      </ref>
      <ref id="CR74">
        <label>74.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Haffner</surname>
            </name>
          </person-group>
          <source>N Engl J Med</source>
          <year>2000</year>
          <volume>343</volume>
          <fpage>923</fpage>
          <pub-id pub-id-type="doi">10.1056/NEJM200009283431304</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Haffner D, Schaefer F, Nissel R, Wuhl E, Tonshoff B, Mehls O (2000) Effect of growth hormone treatment on the adult height of children with chronic renal failure. German Study Group for Growth Hormone Treatment in Chronic Renal Failure. N Engl J Med 343:923&#x2013;930 <pub-id pub-id-type="pmid">11006368</pub-id></citation>
      </ref>
      <ref id="CR75">
        <label>75.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Wang</surname>
            </name>
          </person-group>
          <source>J Endocrinol</source>
          <year>2004</year>
          <volume>180</volume>
          <fpage>247</fpage>
          <pub-id pub-id-type="doi">10.1677/joe.0.1800247</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Wang J, Zhou J, Cheng CM, Kopchick JJ, Bondy CA (2004) Evidence supporting dual, IGF-I-independent and IGF-I-dependent, roles for GH in promoting longitudinal bone growth. J Endocrinol 180:247&#x2013;255 <pub-id pub-id-type="pmid">14765976</pub-id></citation>
      </ref>
      <ref id="CR76">
        <label>76.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Olney</surname>
            </name>
          </person-group>
          <source>Med Pediatr Oncol</source>
          <year>2003</year>
          <volume>41</volume>
          <fpage>228</fpage>
          <pub-id pub-id-type="doi">10.1002/mpo.10342</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Olney RC (2003) Regulation of bone mass by growth hormone. Med Pediatr Oncol 41:228&#x2013;234 <pub-id pub-id-type="pmid">12868124</pub-id></citation>
      </ref>
      <ref id="CR77">
        <label>77.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Loder</surname>
            </name>
          </person-group>
          <source>J Pediatr Orthop</source>
          <year>1997</year>
          <volume>17</volume>
          <fpage>205</fpage>
          <pub-id pub-id-type="doi">10.1097/00004694-199703000-00013</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Loder RT, Hensinger RN (1997) Slipped capital femoral epiphysis associated with renal failure osteodystrophy. J Pediatr Orthop 17:205&#x2013;211 <pub-id pub-id-type="pmid">9075097</pub-id></citation>
      </ref>
      <ref id="CR78">
        <label>78.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fine</surname>
            </name>
          </person-group>
          <source>J Pediatr</source>
          <year>2003</year>
          <volume>142</volume>
          <fpage>539</fpage>
          <pub-id pub-id-type="doi">10.1067/mpd.2003.189</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Fine RN, Ho M, Tejani A, Blethen S (2003) Adverse events with rhGH treatment of patients with chronic renal insufficiency and end-stage renal disease. J Pediatr 142:539&#x2013;545 <pub-id pub-id-type="pmid">12756387</pub-id></citation>
      </ref>
      <ref id="CR79">
        <label>79.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Berard</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>1998</year>
          <volume>12</volume>
          <fpage>304</fpage>
          <pub-id pub-id-type="doi">10.1007/s004670050459</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Berard E, Crosnier H, Six-Beneton A, Chevallier T, Cochat P, Broyer M (1998) Recombinant human growth hormone treatment of children on hemodialysis. French Society of Pediatric Nephrology. Pediatr Nephrol 12:304&#x2013;310 <pub-id pub-id-type="pmid">9655363</pub-id></citation>
      </ref>
      <ref id="CR80">
        <label>80.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Picca</surname>
            </name>
          </person-group>
          <source>Pediatr Nephrol</source>
          <year>2004</year>
          <volume>19</volume>
          <fpage>71</fpage>
          <pub-id pub-id-type="doi">10.1007/s00467-003-1283-1</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Picca S, Cappa M, Martinez C, Moges SI, Osborn J, Perfumo F, Ardissino G, Bonaudo R, Montini G, Rizzoni G (2004) Parathyroid hormone levels in pubertal uremic adolescents treated with growth hormone. Pediatr Nephrol 19:71&#x2013;76 <pub-id pub-id-type="pmid">14634859</pub-id></citation>
      </ref>
      <ref id="CR81">
        <label>81.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Fukagawa</surname>
            </name>
          </person-group>
          <source>Nephron</source>
          <year>1994</year>
          <volume>68</volume>
          <fpage>221</fpage>
        </citation>
        <citation citation-type="display-unstructured">Fukagawa M, Kitaoka M, Yi H, Fukuda N, Matsumoto T, Ogata E, Kurokawa K (1994) Serial evaluation of parathyroid size by ultrasonography is another useful marker for the long-term prognosis of calcitriol pulse therapy in chronic dialysis patients. Nephron 68:221&#x2013;228 <pub-id pub-id-type="pmid">7830860</pub-id></citation>
      </ref>
      <ref id="CR82">
        <label>82.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Okuno</surname>
            </name>
          </person-group>
          <source>Nephrol Dial Transplant</source>
          <year>2003</year>
          <volume>18</volume>
          <fpage>2613</fpage>
          <pub-id pub-id-type="doi">10.1093/ndt/gfg451</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Okuno S, Ishimura E, Kitatani K, Chou H, Nagasue K, Maekawa K, Izumotani T, Yamakawa T, Imanishi Y, Shoji T, Inaba M, Nishizawa Y (2003) Relationship between parathyroid gland size and responsiveness to maxacalcitol therapy in patients with secondary hyperparathyroidism. Nephrol Dial Transplant 18:2613&#x2013;2621 <pub-id pub-id-type="pmid">14605286</pub-id></citation>
      </ref>
      <ref id="CR83">
        <label>83.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Kakuta</surname>
            </name>
          </person-group>
          <source>Am J Kidney Dis</source>
          <year>1999</year>
          <volume>33</volume>
          <fpage>1091</fpage>
        </citation>
        <citation citation-type="display-unstructured">Kakuta T, Fukagawa M, Fujisaki T, Hida M, Suzuki H, Sakai H, Kurokawa K, Saito A (1999) Prognosis of parathyroid function after successful percutaneous ethanol injection therapy guided by color Doppler flow mapping in chronic dialysis patients. Am J Kidney Dis 33:1091&#x2013;1099 <pub-id pub-id-type="pmid">10352197</pub-id></citation>
      </ref>
      <ref id="CR84">
        <label>84.</label>
        <citation citation-type="other">Sch&#xF6;mig M, Ritz E (2000) Management of disturbed calcium metabolism in uraemic patients: 2. Indications for parathyroidectomy. Nephrol Dial Transplant 15 [Suppl 5]:25&#x2013;29</citation>
      </ref>
      <ref id="CR85">
        <label>85.</label>
        <citation citation-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Quarles</surname>
            </name>
          </person-group>
          <source>J Am Soc Nephrol</source>
          <year>2003</year>
          <volume>14</volume>
          <fpage>575</fpage>
          <pub-id pub-id-type="doi">10.1097/01.ASN.0000050224.03126.AD</pub-id>
        </citation>
        <citation citation-type="display-unstructured">Quarles LD, Sherrard DJ, Adler S, Rosansky SJ, McCary LC, Liu W, Turner SA, Bushinsky DA (2003) The calcimimetic AMG 073 as a potential treatment for secondary hyperparathyroidism of end-stage renal disease. J Am Soc Nephrol 14:575&#x2013;583 <pub-id pub-id-type="pmid">12595492</pub-id></citation>
      </ref>
    </ref-list>
    <fn-group>
      <fn>
        <p>The authors are members of the European Pediatric Dialysis Working Group (EPDWG)</p>
      </fn>
    </fn-group>
  </back>
</article>
</pmc-articleset>